---
title: "PDS Biotechnology Corporation (PDSB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PDSB.US.md"
symbol: "PDSB.US"
name: "PDS Biotechnology Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T22:28:10.829Z"
locales:
  - [en](https://longbridge.com/en/quote/PDSB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PDSB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PDSB.US.md)
---

# PDS Biotechnology Corporation (PDSB.US)

## Company Overview

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.pdsbiotech.com](https://www.pdsbiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.67 | 225 | - | - | - |
| PB | 8.02 | - | 5.22 | 3.62 | 2.75 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.03 |
| Highest Target | 15.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PDSB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PDSB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PDSB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PDSB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**